Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
复制标题

阿尔茨海默氏病的新美容类似物的设计,合成以及体外和体内表征。

DOI:
10.1016/j.ejmech.2022.114354
复制
发表时间:
2022-06-05
影响因子:
6.7
通讯作者:
Vázquez S
Vázquez S
中科院分区:
医学1区
文献类型:
--
作者:
Turcu AL;Companys-Alemany J;Phillips MB;Patel DS;Griñán-Ferré C;Loza MI;Brea JM;Pérez B;Soto D;Sureda FX;Kurnikova MG;Johnson JW;Pallàs M;Vázquez S

文献摘要

参考文献

相似文献

目前,在阿尔茨海默病(AD)的几种可获得的对症治疗方法中,美金刚是唯一获得FDA批准的n -甲基- d -天冬氨酸受体(NMDAR)阻滞剂。本研究进一步探索了一系列以苯并精金刚烷为支架的美金刚类似物。大多数新合成的化合物在微摩尔范围内阻断NMDARs,但与先前报道的击中IIc的效力相比,效力较低,分子动力学模拟支持这一结果。随后,对更有效化合物的电生理研究允许将IIc分类为一种低微摩尔、无竞争性、电压依赖性的NMDAR阻滞剂,作为一种类似美金刚的化合物。IIc出色的体外DMPK特性使其成为秀丽隐杆线虫(C. elegans)和5XFAD AD小鼠模型体内研究的有希望的候选者。给药IIc或美金刚改善秀丽隐杆线虫的运动和恢复趋化行为。此外,这两种化合物都能增强5XFAD小鼠的工作记忆,并改变NMDAR和CREB信号,从而可能预防突触功能障碍和调节神经退行性进展。
Currently, of the few accessible symptomatic therapies for Alzheimer’s disease (AD), memantine is the only N-methyl-D-aspartate receptor (NMDAR) blocker approved by the FDA. This work further explores a series of memantine analogs featuring a benzohomoadamantane scaffold. Most of the newly synthesized compounds block NMDARs in the micromolar range, but with lower potency than previously reported hit IIc, results that were supported by molecular dynamics simulations. Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. The excellent in vitro DMPK properties of IIc made it a promising candidate for in vivo studies in Caenorhabditis elegans (C. elegans) and in the 5XFAD mouse model of AD. Administration of IIc or memantine improved locomotion and rescues chemotaxis behavior in C. elegans. Furthermore, both compounds enhanced working memory in 5XFAD mice and modified NMDAR and CREB signaling, which may prevent synaptic dysfunction and modulate neurodegenerative progression.
DOI: 10.1186/s13065-015-0143-y
发表时间: 2015
影响因子: --
作者:
Chen X;Barclay JW;Burgoyne RD;Morgan A
通讯作者: Morgan A
DOI: 10.1016/j.bmc.2008.10.028
发表时间: 2008-12-01
影响因子: 3.5
作者:
Camps P;Duque MD;Vázquez S;Naesens L;De Clercq E;Sureda FX;López-Querol M;Camins A;Pallàs M;Prathalingam SR;Kelly JM;Romero V;Ivorra D;Cortés D
通讯作者: Cortés D
DOI: 10.1523/jneurosci.4262-04.2005
发表时间: 2005-03-30
影响因子: 5.3
作者:
Blanpied,TA;Clarke,RJ;Johnson,JW
通讯作者: Johnson,JW
DOI: 10.3390/ijms22126298
发表时间: 2021-06-11
影响因子: 5.6
作者:
Back MK;Ruggieri S;Jacobi E;von Engelhardt J
通讯作者: von Engelhardt J
DOI: 10.1016/j.bbadis.2018.03.019
发表时间: 2018-06-01
影响因子: 6.2
作者:
Carvajal, Francisco J.;Mira, Rodrigo G.;Cerpa, Waldo
通讯作者: Cerpa, Waldo